Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 6/20 | 0.44 |
| ▸ | ATF1 | P18846 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | XPO1 | O14980 | 3/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | JUN | P05412 | 2/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1759818 | 0.86 | MAPT (0.53) | NFKB1ATF1KDM4EMAPTCNR2 | |
| SCHEMBL14556246 | 0.84 | KDM4E (0.51) | NFKB1ATF1KDM4EMAPTCNR2 | |
| SCHEMBL2118779 | 0.78 | KDM4E (0.47) | NFKB1ATF1KDM4EXPO1ASPH | |
| SCHEMBL8544671 | 0.76 | XPO1 (0.42) | NFKB1ATF1KDM4ECNR2XPO1 | |
| SCHEMBL4763537 | 0.76 | HPGD (0.54) | KDM4EGAATDP1POLBLMNA | |
| SCHEMBL8546804 | 0.76 | NFKB1 (0.56) | NFKB1ATF1KDM4ECNR2XPO1 | |
| SCHEMBL9564859 | 0.76 | XPO1 (0.46) | NFKB1ATF1KDM4EMAPTCNR2 | |
| SCHEMBL2745323 | 0.76 | TDP1 (0.51) | KDM4EGAATDP1POLBLMNA | |
| SCHEMBL1932956 | 0.76 | TDP1 (0.40) | KDM4EMAPTGAATDP1POLB | |
| SCHEMBL480176 | 0.75 | XPO1 (0.62) | NFKB1ATF1XPO1JUNNFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2499121-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011057973-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | TAAR1, HCRTR1, NPY1R | NFKB1 4253/4885ATF1 1057/4885KDM4E 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.